Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):202-209. doi: 10.1089/mab.2021.0068. Epub 2022 Aug 4.
Blockade of the PD-L1/PD-1 pathway has proven to be a broadly effective cancer immunotherapy. FDA-approved therapeutic monoclonal antibodies (mAbs) targeting the pathway have high affinity, blocking capacity, and low antibody effector activity. A number of rat antimouse mAbs have been used to model cancer immunotherapy in mouse models. We set forth the amino acid sequences of mAbs specific for mouse PD-1 (29F.1A12) and PD-L1 (10F.9G2) and compare their avidities, blocking capacities, biological activities, and epitope recognition with other commonly used mAbs. Further manipulation of these sequences should facilitate better modeling of immunotherapy in mouse models and the generation of novel agents.
阻断 PD-L1/PD-1 通路已被证明是一种广泛有效的癌症免疫疗法。经美国食品和药物管理局 (FDA) 批准的靶向该通路的治疗性单克隆抗体 (mAb) 具有高亲和力、阻断能力和低抗体效应活性。许多针对小鼠的抗鼠 mAb 已被用于在小鼠模型中模拟癌症免疫疗法。我们列出了针对小鼠 PD-1 (29F.1A12) 和 PD-L1 (10F.9G2) 的 mAb 的氨基酸序列，并比较了它们的亲和力、阻断能力、生物学活性和表位识别与其他常用 mAb 的差异。进一步对这些序列进行操作，应有助于更好地在小鼠模型中模拟免疫疗法，并产生新型药物。
